Clinical Trials Logo

Clinical Trial Summary

Overt hypothyroidism is associated with increased risk for cardiovascular disease (CVD) as indicated by hypertension, hypercholesterolemia, and increased low-density lipoprotein cholesterol (LDL-C) levels. Mild hypothyroidism, also called subclinical hypothyroidism [SH] is highly prevalent in elderly subjects, especially in women older than 50 years of age. Whether SH is related as a risk for premature CVD is controversial. It was shown that SH is associated with elevated lipids levels, particularly LDL-cholesterol. However recent evidence suggests that the 'quality' rather than only the 'quantity' of LDL-cholesterol exerts a direct influence on the cardiovascular risk. LDL-cholesterol comprises multiple distinct subclasses that differ in their atherogenic potential. Thus, the proposed study protocol is intended to evaluate the different LDL lipoproteins subclasses in patients with subclinical hypothyroidism.


Clinical Trial Description

Overt hypothyroidism is associated with increased risk for cardiovascular disease[CVD] as indicated by hypertension, hypercholesterolemia, and increased low-density lipoprotein cholesterol (LDL-C) levels.However, not all patients have hypertension or abnormal lipid profiles, suggesting that other factors may be involved as collagen-induced platelet aggregation or relaxation of vascular smooth muscle, elevated plasma homocysteine and C- reactive protein [CRP] levels have been reported in overt hypothyroidism and have been proposed as an independent risk factor for CVD.

Subclinical hypothyroidism [SH] is highly prevalent in elderly subjects, especially in women older than 50 years of age. Whether SH is related as a risk for premature CVD is controversial. Previously, we have demonstrated that SH in middle-aged women is associated with hypertension, hypertriglyceridemia, and elevated total cholesterol/HDL- cholesterol ratio.SH was associated with elevated plasma total cholesterol and LDL-cholesterol, decreased LDL-cholesterol/LDL-triglycerides due to decreased hepatic lipase activity. The influence of SH on lipids was directly proportional to the degree of TSH elevation.

Atherosclerosis is a diffuse disease formerly considered lipid storage disease, actually involves an ongoing inflammatory response. Elevated circulating levels of acute phase proteins, cytokines, and cell adhesion molecules indicate that inflammatory processes are occurring systematically. Metabolic syndrome is a collection of metabolic risk factors, probably of more than one cause, that appear to promote the development of atherosclerotic CVD. Hypertension, dyslipidemia and hyperglycemia are the most widely recognized characteristics of the metabolic syndrome. Individuals with metabolic syndrome manifest a prothrombotic state as well as a proinflammatory state. Insulin resistance is recognized as a chronic low-level inflammatory state. Insulin action is an important effector mechanism of the proinflammatory cytokines in CVD. Insulin resistance was proposed as the common preceding factor of hypertension, LDL and HDL-cholesterol, hypertriglyceridemia, abdominal obesity and altered glucose metabolism, linking all of these to the development of CVD. Thus, inflammation, metabolic syndrome and insulin resistance are strongly associated and play an important role in the pathogenesis of atherosclerosis. In a cross-sectional analysis, subjects with SH had a significantly higher prevalence of CVD than euthyroid subjects. There were more cardiovascular deaths in subjects with SH than in the euthyroid population. These data suggest that SH may be an independent risk factor for CVD. It is not clear yet whether patients with SH have cardiovascular risk, as do patients with overt hypothyroidism, and whether metabolic syndrome and insulin resistance already exist in untreated patients with SH.

This question was recently studied by our group. We evaluated untreated patients with SH. the percentage of MS in patients (41.5%) was significantly higher than in controls (12.2%; p=0.003]. SH had significantly higher likelihood of cardiovascular risks [odds ratio 6.26, 95% confidence interval (CI) 1.6 - 4.49, p= 0.008 for MS].

We conclude that SH is associated with greater probability of MS. Recent evidence suggests that the 'quality' rather than only the 'quantity' of LDL exerts a direct influence on the cardiovascular risk. LDL comprises multiple distinct subclasses that differ in size, density, physicochemical composition, metabolic behaviour and atherogenicity. There are at least four major subspecies of LDL (e.g. large LDL-I, medium LDL-II, small LDL-III, very small LDL-IV) and the predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor.

Thus, the proposed study protocol is intended to evaluate lipoprotein phenotype and LDL size and subclasses in patients with subclinical Hypothyroidism. ;


Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT00962221
Study type Observational
Source HaEmek Medical Center, Israel
Contact
Status Terminated
Phase N/A
Start date October 2009
Completion date October 2012

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05019118 - Dietary Intervention With Únicla Dairy Products (DANTIAN) N/A
Completed NCT01838031 - Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study N/A
Completed NCT01335802 - Relation Between Subclinical Hypothyroidism and Outcome of Pregnancy
Completed NCT00388297 - Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy Phase 3
Completed NCT03898622 - Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without TRR. Phase 3
Completed NCT01985204 - Iodine Supplementation in Obesity N/A
Recruiting NCT06041204 - Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism N/A
Completed NCT01660126 - Thyroid Hormone Replacement for Subclinical Hypothyroidism Phase 4
Completed NCT04354896 - The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism Phase 4
Completed NCT02090907 - Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism Phase 2/Phase 3
Completed NCT04288115 - Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism Phase 4
Completed NCT01853579 - The TRUST Study - Depression Substudy Phase 4
Completed NCT00921050 - Subclinical Hypothyroidism and Mind in the Elderly Phase 2/Phase 3
Completed NCT00535561 - Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism Phase 1
Completed NCT00498238 - The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients With Subclinical Hypothyroidism N/A
Completed NCT03036956 - The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan N/A
Completed NCT02061111 - NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease
Completed NCT01832753 - Treatment Trial of Subclinical Hypothyroidism in Down Syndrome N/A
Completed NCT02399475 - Mechanistic Study of Subclinical Hypothyroidism In the Elderly N/A
Completed NCT00437931 - Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction N/A